In:
International Journal of Cancer, Wiley, Vol. 145, No. 4 ( 2019-08-15), p. 1007-1019
Abstract:
What's new? Esophageal squamous cell carcinoma (ESCC) is among the most common and deadliest forms of esophageal malignancy. Chemotherapy remains the mainstay of treatment, even though many ESCC patients experience disease progression despite therapy. Here, the authors investigated a novel agent for ESCC, the prenylated flavonoid xanthohumol. In ESCC cells, xanthohumol was found to directly target AKT kinase, inhibiting AKT activity, suppressing cell proliferation, and inducing apoptosis. In a patient‐derived xenograft mouse model, xanthohumol reduced tumor volume specifically in high AKT‐expressing tumors, with little effect on low AKT tumors. The data suggest that AKT targeting is a promising therapeutic strategy in ESCC.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8